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Abstract: There is a strong need to find new, good biomarkers of head and neck squamous cell
carcinoma (HNSCC) because of the bad prognoses and high mortality rates. The aim of this study
was to identify the potential biomarkers in HNSCC that have differences in their DNA methylome
and potentially premalignant oral lesions, in comparison to healthy oral mucosa. In this study,
32 oral samples were tested: nine healthy oral mucosae, 13 HNSCC, and 10 oral lesions for DNA
methylation by the Infinium MethylationEPIC BeadChip. Our findings showed that a panel of genes
significantly hypermethylated in their promoters or specific sites in HNSCC samples in comparison to
healthy oral samples, which are mainly oncogenes, receptor, and transcription factor genes, or genes
included in cell cycle, transformation, apoptosis, and autophagy. A group of hypomethylated genes
in HNSCC, in comparison to healthy oral mucosa, are mainly involved in the host immune response
and transcriptional regulation. The results also showed significant differences in gene methylation
between HNSCC and potentially premalignant oral lesions, as well as differently methylated genes
that discriminate between oral lesions and healthy mucosa. The given methylation panels point
to novel potential biomarkers for early diagnostics of HNSCC, as well as potentially premalignant
oral lesions.
Keywords: DNA methylation; head and neck squamous cell carcinoma (HNSCC); potentially
premalignant oral lesions; healthy oral mucosa; human papillomavirus (HPV)
1. Introduction
Head and neck squamous cell carcinoma (HNSCC), which encompasses tumors of the oral and
nasal cavities, paranasal sinuses, pharynx, and larynx, is the 6th most frequent malignancy in the
world, with over 650,000 new cases diagnosed each year [1]. Although the overall survival of patients
with oral cancer has improved during the past 20 years, it has only improved marginally; mainly due
to the advanced clinical stage at diagnosis and the high rates of treatment failure associated with this
advanced disease [2].
The most important risk factors identified so far for HNSCC are excessive tobacco [3,4] and
alcohol consumption [5–7], together with high-risk types of human papillomavirus (HPV) [8–10].
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Although the global incidence of HNSCC is declining, the incidence of HPV related HNSCC, especially
oropharyngeal and oral squamous cell carcinoma (OPSCC and OSCC, respectively) is rapidly increasing
over the last few decades [11]. Recent findings emphasize the importance of epigenetic changes,
such as DNA methylation and alterations including micro RNAs (miRNA), in HNSCC progression
and implicate the very role of tobacco and alcohol [12], as well as HPV [13] in those changes.
The HNSCCs are one of the cancer types with the worst prognosis and with a high mortality
of patients, hence, there is a strong need to find new biomarkers of this disease [14,15]. The most
appropriate biomarkers would be those pointing out changes on the cellular level before carcinoma
can be detected or even before carcinoma occurrence. The epigenetic biomarkers, such as methylated
genes could efficiently point to changes before cancers can be clinically detected and help us better
understand tumorigenesis and hopefully improve cancer treatment and prevention [16,17]. Some of
these potential biomarkers could also differentiate between the groups of potentially premalignant
oral lesions that show possible premalignant transformation, such as oral lichen planus (OLP) and
oral lichenoid lesions (OLL), whose treatment is different from each other despite their high clinical
and histopathological similarities [18–20]. Namely, OLP is a chronic immunological mucocutaneous
disorder of unknown etiology, while OLL is usually of known etiology, being a lichenoid contact
stomatitis [21].
DNA methylation is the most studied epigenetic change in human diseases, especially cancer
because it is apparently stable under most storage conditions, even as histological preparations [22].
Altered DNA methylation is one of the possible factors associated even with the HNSCC development.
The focus of this study was to explore DNA methylation changes that are significantly deregulated in
HNSCC samples, particularly OPSCC and OSCC, and potentially premalignant oral lesions (such as
OLP and OLL) in comparison to healthy oral mucosa. Identifying DNA methylome differences by
means of the Infinium MethylationEPIC BeadChip array (Illumina, San Diego, California, United States)
on the level of methylated genes, gene promoters, and individual 5′-cytosine-phosphate-guanine-3′
(CpG) sites between HNSCC, potentially premalignant oral lesions, and healthy oral mucosa enables
us to suggest novel potential biomarkers for the identification of HNSCC and potentially premalignant
oral lesions.
2. Results
2.1. HPV Status
HPV DNA was found in nine of 32 samples, of which are five cancer samples, three potentially
premalignant oral lesions samples, and one control sample (healthy mucosa) (Figure S1). HPV 16
was found in all five HPV positive cancer samples. HPV 58 was found in one OLP sample positive,
while undetermined HPV types were found in one OLP, one OLL, and one control sample.
2.2. Overall DNA Methylation Findings
After pre-processing, normalization, and batch correction of Infinium MethylationEPIC BeadChip
data in ChAMP, 679,851 probes were retained for analysis by the RnBeads package. The inclusion
criteria was the value of the mean difference across all sites in a region (mean.mean.diff; MMD),
the highest and the lowest values from the Illumina assay data. The cut-off values were: FDR adjusted
p-value ≤ 0.05 and mean methylation difference ≥ |0.2|. For every set of data, the list of first 15
genes, the best significantly differentiated between groups of samples in methylation, i.e., hyper- or
hypomethylated, is presented (the mean methylation difference was ≥ |0.44|). The whole list of genes,
besides a large number of defined genes includes not annotated (NA) genes, pseudogenes, and RNA
genes (could be provided upon request).
Within the exploratory analysis, the principal component analysis (PCA) showed that all samples
clustered within three distinct clusters: Cancer, lesions, and controls (Figure 1). One healthy oral mucosa
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sample of 32 oral samples analyzed by the Infinium MethylationEPIC BeadChip was automatically
excluded during filtering and normalization steps (Figures 1–3, and Figure S1).
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Figure 1. Infinium MethylationEPIC BeadChip findings: Samples grouping by the principal 
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The unsupervised hierarchical clustering analysis based on all investigated methylation sites 
across the genome and all methylation values showed good clustering of cancer samples on one side, 
however control samples and potentially premalignant oral lesions were clustered together on the 
other side (Figure 2A). The situation was similar when visualizing only the top 1000 most variable 
positions (Figure 2B). As expected, global cancer hypomethylation can be seen in both figures as more 
CpG sites exhibit lower methylation values in cancer cluster. The heatmap representation of samples 
clustering for the top fifteen hypermethylated and the top fifteen hypomethylated CpG gene sites in 
cancer tissue compared to control healthy tissue also showed good clustering of cancer samples on 
one side and control samples on the other, while most of the potentially premalignant oral lesions 
were clustered between those two groups (Figure 3). 
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Figure 2. Infinium MethylationEPIC BeadChip findings: Hierarchical clustering of samples based on 
all methylation values. (A) The heatmap displays methylation percentiles per sample. (B) The 
heatmap displays only selected sites/regions with the highest variance across all samples. Green: 
HNSCC samples, oropharyngeal cancer (n = 6) and oral cancer (n = 7), orange: Oral lesions, OLP (n = 
8) and OLL (n = 2), violet: Healthy oral mucosa (n = 8). 
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The top fifteen genes significantly hypermethylated in their promoters in cancer tissues in 
comparison to healthy tissues are: GPRC5D, TMPRSS11B, PIAS2, ARG1, SRPK2, AADACL2, RGPD4, 
SPRR3, DEGS1, TXNDC8, SH3TC1, ZPLD1, FBXO2, ATG16L1, and GRHL1 (Table 1). The FDR 
adjusted p-value was < 0.05 and the difference in the average methylation value between 0.78 and 
0.44. The hypermethylated genes are mostly involved in different cellular enzymatic reactions and 
autophagy. 
Table 1. Hypermethylated gene promoter methylation in HNSCC tissue compared to control healthy 
tissue and potentially premalignant oral lesions, and in potentially premalignant oral lesions 
compared to control healthy tissue. The list is merged of top fifteen differentially methylated genes 
according to the extent of methylation difference value. 
Gene Name Function MMD * p-Value ** 
HNSCC Tissue vs. Healthy Tissue 
GPRC5D G protein-coupled receptor 0.78 6.49 × 10−7 
TMPRSS11B Transmembrane protease 0.76 2.04 × 10−8 
PIAS2 Sumoylation 0.66 1.22 × 10−6 
ARG1 Arginase activity 0.64 2.50 × 10−7 
SRPK2 Protein kinase 0.62 1.30 × 10−6 
AADACL2 Hydrolase activity 0.59 7.38 × 10−7 
RGPD4 RNA transport 0.58 4.71 × 10−6 
SPRR3 Structural molecule activity 0.53 2.44 × 10−7 
DEGS1 Desaturase activity 0.49 2.04 × 10−8 
TXNDC8 Oxidoreductase activity 0.48 1.15 × 10−5 
SH3TC1 Myelination 0.47 2.05 × 10−6 
ZPLD1 Cerebral malformations 0.47 6.17 × 10−6 
FBXO2 Ubiquitination 0.46 0.000236 
ATG16L1 Autophagy 0.46 0.000306 
GRHL1 Transcription factor 0.44 5.12 × 10−7 
Figure 2. Infinium MethylationEPIC BeadChip findings: Hierarchical clustering of samples based on
all methylation values. (A) The heatmap displays methylation percentiles per sample. (B) The heatmap
displays only selected sites/regions with the highest variance across all samples. Green: HNSCC
samples, oropharyngeal cancer (n = 6) and oral cancer (n = 7), orange: Oral lesions, OLP (n = 8) and OLL
(n = 2), violet: Healthy oral mucosa (n = 8).
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in cancer tissue compared to control healthy tissue (according to the methylation difference value; 
Tables 3 and 4). Left side (green): HNSCC samples (n = 13; kbd10–kbd11); right side (violet): Healthy 
oral mucosa (n = 8; 2010-804, 2017-1237–2017-1227, 2017-1236, 2010-823); middle (orange): Oral lesions 
(n = 10; 2010-786–2010-865, 2010-777, 2014-1003, 2009-757, 2010-784). 
Table 3. Hypermethylated 5′-cytosine-phosphate-guanine-3′ (CpG) sites methylation in HNSCC 
tissue compared to control healthy tissue and potentially premalignant oral lesions, and in potentially 
premalignant oral lesions compared to control healthy tissue. The list is merged of top fifteen 
differentially methylated genes according to the extent of methylation difference value. 
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LMBR1L Probable receptor cg12348519 0.93 4.59 × 10−8 
CDH1 Adhesions, mobility, and proliferation cg08285862 0.92 3.49 × 10−8 
EIF6 Initiation of translation cg09957666 0.92 1.96 × 10−8 
C16orf70 Not known cg03664901 0.92 3.48 × 10−8 
ETNK2 Transferase and kinase activity cg12142497 0.92 5.33 × 10−8 
C11orf73 Cellular response to heat stress cg23450586 0.91 5.01 × 10−9 
ADARB2 RNA editing cg26569590 0.91 2.10 × 10−8 
GAB1 Cellular growth, transformation, and apoptosis cg23020414 0.91 2.83 × 10−8 
ITPR3 Metabolism and growth cg05876496 0.91 6.35 × 10−8 
Figure 3. Infinium MethylationEPIC BeadChip findings: Heatmap representation of sa ples clustering
for the top fifteen hy erm th lated (blue) and top fifteen hypomethylated (red) sites in cancer
tissue compared to control healthy tissue (according to the methylation difference value; Tables 3 and 4).
Left side (green): HNSCC samples (n = 13; kbd10–kbd11); right side (violet): Healthy oral mucosa
(n = 8; 2010-804, 2017-1237–2017-1227, 2017-1236, 2010-823); middle (orange): Oral lesions (n = 10;
2010-786–2010-865, 2010-777, 2014-1003, 2009-757, 2010-784).
The unsupervised hierarchical clustering analysis based on all investigated methylation sites
across the genome and all methylation values s owed good clustering of cancer samples on one side,
however control sa ples and potentially premalignant oral lesions were clustered together on the
other side (Figure 2A). The situatio was similar when visualizing only the top 1000 most variable
positions (Figure 2B). As expected, global cancer hypomethylation can be seen in both figures as more
CpG sites exhibit lower methylation values in cancer cluster. The heatmap representation of samples
clustering for the top fifteen hypermethyl ted and the top fifteen hypomethylated CpG gene sites in
cancer tissue compared to control healthy tissue also showed good clustering of cancer samples on one
side and control samples on the other, while most of the potentially premalignant oral lesions were
clustered between those two groups (Figure 3).
2.3. Differentially Methylated G ne Promoters in HNSCC Tissue Compared to Control Tissue
The top fifteen genes significantly hypermethylated in their promoters in cancer tissues in
comparison to healthy tissues are: GPRC5D, TMPRSS11B, PIAS2, ARG1, SRPK2, AADACL2, RGPD4,
SPRR3, DEGS1, TXNDC8, SH3TC1, ZPLD1, FBXO2, ATG16L1, and GRHL1 (Table 1). The FDR
adjusted p-value was < 0.05 and the difference in the average methylation value between 0.78 and 0.44.
The hypermethylated genes are mostly involved in different cellular enzymatic reactions and autophagy.
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Table 1. Hypermethylated gene promoter methylation in HNSCC tissue compared to control healthy
tissue and potentially premalignant oral lesions, and in potentially premalignant oral lesions compared
to control healthy tissue. The list is merged of top fifteen differentially methylated genes according to
the extent of methylation difference value.
Gene Name Function MMD * p-Value **
HNSCC Tissue vs. Healthy Tissue
GPRC5D G protein-coupled receptor 0.78 6.49 × 10−7
TMPRSS11B Transmembrane protease 0.76 2.04 × 10−8
PIAS2 Sumoylation 0.66 1.22 × 10−6
ARG1 Arginase activity 0.64 2.50 × 10−7
SRPK2 Protein kinase 0.62 1.30 × 10−6
AADACL2 Hydrolase activity 0.59 7.38 × 10−7
RGPD4 RNA transport 0.58 4.71 × 10−6
SPRR3 Structural molecule activity 0.53 2.44 × 10−7
DEGS1 Desaturase activity 0.49 2.04 × 10−8
TXNDC8 Oxidoreductase activity 0.48 1.15 × 10−5
SH3TC1 Myelination 0.47 2.05 × 10−6
ZPLD1 Cerebral malformations 0.47 6.17 × 10−6
FBXO2 Ubiquitination 0.46 0.000236
ATG16L1 Autophagy 0.46 0.000306
GRHL1 Transcription factor 0.44 5.12 × 10−7
HNSCC Tissue vs. Oral Lesions
RAD51B RAD51 Paralog B 0.85 2.53 × 10−8
BARX2 BARX Homeobox 2 0.81 3.94 × 10−8
SLC5A10;FAM83G Solute Carrier Family 5 Member 10 0.78 2.58 × 10−8
NINL Ninein Like 0.77 3.96 × 10−8
NSMCE2 NSE2/MMS21 Homolog, SMC5-SMC6 Complex SUMO Ligase 0.76 6.36 × 10−7
PGAP2 Post-GPI Attachment to Proteins 2 0.75 9.48 × 10−8
INO80C INO80 Complex Subunit C 0.74 1.96 × 10−9
IL34 Interleukin 34 0.74 2.20 × 10−9
ZNF516 Zinc Finger Protein 516 0.73 4.90 × 10−8
GFOD2 Glucose-Fructose Oxidoreductase Domain Containing 2 0.73 1.36 × 10−7
PARD3 Par-3 Family Cell Polarity Regulator 0.73 1.36 × 10−7
MCEE Methylmalonyl-CoA Epimerase 0.72 2.89 × 10−8
POLM DNA Polymerase Mu 0.72 3.93 × 10−7
ASPG Asparaginase 0.71 4.43 × 10−8
TBC1D2 TBC1 Domain Family Member 2 0.71 3.74 × 10−7
Oral Lesions vs. Healthy Tissue
SLC5A10;FAM83G Solute Carrier Family 5 Member 10 0.78 2.58 × 10−8
TBC1D2 TBC1 Domain Family Member 2 0.71 3.74 × 10−7
SH3BP5L SH3 Binding Domain Protein 5 Like 0.70 2.68 × 10−7
VANGL1 VANGL Planar Cell Polarity Protein 1 0.69 6.49 × 10−7
DLEC1 Deleted in Lung And Esophageal Cancer 1 0.61 3.84 × 10−6
TGOLN2 Trans-Golgi Network Protein 2 0.61 3.79 × 10−7
CTBP2 C-Terminal Binding Protein 2 0.59 4.99 × 10−6
PPP1CB Protein Phosphatase 1 Catalytic Subunit Beta 0.56 2.20 × 10−6
VPS52 VPS52, GARP Complex Subunit 0.53 8.05 × 10−6
MEPCE Methylphosphate Capping Enzyme 0.52 2.89 × 10−7
HDAC4 Histone Deacetylase 4 0.51 6.47 × 10−6
ARAP1 ArfGAP with RhoGAP Domain, Ankyrin Repeat, and PH Domain 1 0.50 4.77 × 10−7
TCF20 Transcription Factor 20 0.49 4.14 × 10−5
NDUFS7 NADH:Ubiquinone Oxidoreductase Core Subunit S7 0.49 0.00017
GATAD2A GATA Zinc Finger Domain Containing 2A 0.47 3.58 × 10−8
* Mean difference (MD) across all sites in a region (mean.mean.diff); ** false discovery rate (FDR) adjustment
combined p-value (comb.p.adj.fdr).
The top fifteen genes that were significantly hypomethylated in their promoters in cancer tissues
in comparison to healthy tissues are: TRBC2, DGAT2, ALG1L, PDE4D, TRDC, DNAJC6, IGKV3-20,
TMEM150B, LAIR2, UBQLN3, ANKFN1, MS4A1, CCT8L2, SPOCK1, and IGHV4-39 (Table 2). The FDR
adjusted p-value was < 0.05 and the difference in the average methylation value between −0.80 and
−0.61. The hypomethylated genes are mainly involved in the immune response.
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Table 2. Hypomethylated gene promoter methylation in HNSCC tissue compared to control healthy
tissue and potentially premalignant oral lesions, and in potentially premalignant oral lesions compared
to control healthy tissue. The list is merged of top fifteen differentially methylated genes according to
the extent of methylation difference value.
Gene Name Function MMD * p-Value **
HNSCC Tissue vs. Healthy Tissue
TRBC2 T cell receptor −0.80 2.48 × 10−7
DGAT2 Acyltransferase activity −0.70 2.48 × 10−7
ALG1L Transferase activity −0.70 3.29 × 10−5
PDE4D Enzyme binding −0.68 1.06 × 10−5
TRDC T cell receptor −0.67 1.46 × 10−5
DNAJC6 Phosphatase activity −0.67 1.63 × 10−6
IGKV3-20 Immunoglobulin receptor binding −0.66 1.71 × 10−5
TMEM150B Transmembrane protein −0.66 8.13 × 10−5
LAIR2 Innate immune response −0.65 1.81 × 10−5
UBQLN3 Protein degradation −0.64 2.57 × 10−6
ANKFN1 Not known −0.64 1.71 × 10−7
MS4A1 Differentiation of B-cells −0.63 3.80 × 10−5
CCT8L2 Channel activity −0.62 3.59 × 10−6
SPOCK1 Not known −0.61 5.06 × 10−5
IGHV4-39 Antigen recognition −0.61 9.44 × 10−7
HNSCC Tissue vs. Oral Lesions
ART4 ADP-Ribosyltransferase 4 (Dombrock Blood Group) −0.88 7.92 × 10−11
EPB41L3 Erythrocyte Membrane Protein Band 4.1 Like 3 −0.87 6.18 × 10−11
ESRRG Estrogen Related Receptor Gamma −0.86 8.51 × 10−9
ENPP1 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 −0.86 1.26 × 10−9
GNG7 G Protein Subunit Gamma 7 −0.86 4.75 × 10−9
PAPSS2 3′-Phosphoadenosine 5′-Phosphosulfate Synthase 2 −0.85 4.10 × 10−9
NGEF Neuronal Guanine Nucleotide Exchange Factor −0.84 1.87 × 10−9
HIPK4 Homeodomain Interacting Protein Kinase 4 −0.84 6.69 × 10−9
GPR158 G Protein-Coupled Receptor 158 −0.83 9.82 × 10−10
GSG1L GSG1 Like −0.83 1.04 × 10−8
SMPD3 Sphingomyelin Phosphodiesterase 3 −0.83 1.64 × 10−8
GDF2 Growth Differentiation Factor 2 −0.83 5.15 × 10−10
RERE Arginine-Glutamic Acid Dipeptide Repeats −0.82 2.19 × 10−8
CDH13 Cadherin 13 −0.82 1.81 × 10−10
HS3ST4 Heparan Sulfate-Glucosamine 3-Sulfotransferase 4 −0.82 1.02 × 10−8
Oral Lesions vs. Healthy Tissue
ART4 ADP-Ribosyltransferase 4 (Dombrock Blood Group) −0.88 7.92 × 10−11
ENPP1 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 −0.86 1.26 × 10−9
GNG7 G Protein Subunit Gamma 7 −0.86 4.75 × 10−9
PKD1L3 Polycystin 1 Like 3, Transient Receptor Potential Channel Interacting −0.81 2.20 × 10−9
PLXNC1 Plexin C1 −0.81 1.41 × 10−9
CAMK2B Calcium/Calmodulin Dependent Protein Kinase II Beta −0.79 1.05 × 10−8
CACNA1S Calcium Voltage–Gated Channel Subunit Alpha1 S −0.78 8.18 × 10−9
SCGB1D1 Secretoglobin Family 1D Member 1 −0.78 2.34 × 10−7
VPS13D Vacuolar Protein Sorting 13 Homolog D −0.76 6.12 × 10−8
DLGAP4 DLG Associated Protein 4 −0.76 6.37 × 10−9
LRP1B LDL Receptor Related Protein 1B −0.76 1.12 × 10−9
COL2A1 Collagen Type II Alpha 1 Chain −0.75 1.30 × 10−8
SLC24A3 Solute Carrier Family 24 Member 3 −0.74 3.07 × 10−9
TBC1D8 TBC1 Domain Family Member 8 −0.74 1.84 × 10−8
ABCC8 ATP Binding Cassette Subfamily C Member 8 −0.73 3.58 × 10−9
* Mean difference (MD) across all sites in a region (mean.mean.diff); ** false discovery rate (FDR) adjustment
combined p-value (comb.p.adj.fdr).
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2.4. Differentially Methylated CPG Sites in HNSCC Tissue Compared to Control Tissue
From the complete list of differentially methylated CpG sites, only those falling within or near
defined genes were selected, while all other sites for which the biologic relevance could not be evaluated
were excluded (Figure 3). Thus, the top fifteen significantly hypermethylated sites in cancer tissues in
comparison to healthy tissues are: LMBR1L, CDH1, EIF6, C16orf70, ETNK2, C11orf73, ADARB2, GAB1,
ITPR3, WDR61, PGAP2, DDX10, DGKH, RAB40C, and BEAN1 genes (Table 3). The FDR adjusted
p-value was < 0.05 and the difference between mean methylation values across sites between 0.93 and
0.89. The hypermethylated genes are mostly involved in translation processes and cellular growth,
transformation, and proliferation.
The top fifteen genes significantly hypomethylated on different sites across the genome (5′UTR,
3′UTR, TSS1500, TSS200, 1st exon, exon body) in cancer tissues in comparison to healthy tissues are:
ATXN1, PPP2R2C, CCR6, RAB37, DUSP27, ZNF521, SLC6A17, SPIN1, CXCR1, SPTBN1, NBAS, NRG3,
COL5A1, CDX1, and BATF3 (Table 4). The FDR adjusted p-value was < 0.05 and the difference between
mean methylation values across sites between −0.96 and −0.89. The hypomethylated genes are mostly
involved in transcriptional and immune regulation.
2.5. Aberrant Methylation in Potentially Premalignant Oral Lesions
The aberrant methylation in gene promoters and CpG sites within defined genes in HNSCC tissue
compared to potentially premalignant oral lesions, OLP and OLL, and in oral lesions compared to
healthy tissue are shown in Table 1, Table 2, Table 3, and Table 4, respectively.
The top fifteen genes significantly hypermethylated in their promoters that could distinguish
HNSCC from potentially premalignant oral lesions are: RAD51B, BARX2, SLC5A10/FAM83G, NINL
NSMCE2, PGAP2, INO80C, IL34, ZNF516, GFOD2, PARD3, MCEE, POLM, ASPG, and TBC1D2
(Table 1). The top fifteen genes significantly hypomethylated in their promoters in HNSCC compared
to potentially premalignant oral lesions are: ART4, EPB41L3, ESRRG, ENPP1, GNG7, PAPSS2, NGEF,
HIPK4, GPR158, GSG1L, SMPD3, GDF2, RERE, CDH13, and HS3ST4 (Table 2).
The top fifteen genes significantly hypermethylated (SLC5A10, TBC1D2, SH3BP5L, VANGL1,
DLEC1, TGOLN2, CTBP2, PPP1CB, VPS52, MEPCE, HDAC4, ARAP1, TCF20, NDUFS7, and GATAD2A)
and the top fifteen genes significantly hypomethylated in their promoters (ART4, ENPP1, GNG7,
PKD1L3, PLXNC1, CAMK2B, CACNA1S, SCGB1D1, VPS13D, DLGAP4, LRP1B, COL2A1, SLC24A3,
TBC1D8, and ABCC8) that could distinguish potentially premalignant oral lesions from healthy oral
mucosa are shown in Tables 1 and 2. The top fifteen genes significantly hypermethylated (GRIP1,
MTMR10, RBM47, MPHOSPH9, FOXK1, SNX3, CIT, ZBTB38, DRD3, SPPL3, ZNF407, ADAMTSL1,
GNAT3, L3MBTL3, and EEPD1) and the top fifteen genes significantly hypomethylated (PHACTR1,
MARCH8, PPP1R1B, HDAC4, IL22RA2, CAMKK2, INPP5D, CSGALNACT1, GTDC1, IGSF3, HELZ,
DEFA4, AK5, LHFPL2, and STK10) on different sites across the genome in potentially premalignant oral
lesions in comparison to healthy oral mucosa are shown in Tables 3 and 4.
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Table 3. Hypermethylated 5′-cytosine-phosphate-guanine-3′ (CpG) sites methylation in HNSCC tissue compared to control healthy tissue and potentially premalignant
oral lesions, and in potentially premalignant oral lesions compared to control healthy tissue. The list is merged of top fifteen differentially methylated genes according
to the extent of methylation difference value.
Gene Name Function cg Position MMD * p-Value **
HNSCC Tissue vs. Healthy Tissue
LMBR1L Probable receptor cg12348519 0.93 4.59 × 10−8
CDH1 Adhesions, mobility, and proliferation cg08285862 0.92 3.49 × 10−8
EIF6 Initiation of translation cg09957666 0.92 1.96 × 10−8
C16orf70 Not known cg03664901 0.92 3.48 × 10−8
ETNK2 Transferase and kinase activity cg12142497 0.92 5.33 × 10−8
C11orf73 Cellular response to heat stress cg23450586 0.91 5.01 × 10−9
ADARB2 RNA editing cg26569590 0.91 2.10 × 10−8
GAB1 Cellular growth, transformation, and apoptosis cg23020414 0.91 2.83 × 10−8
ITPR3 Metabolism and growth cg05876496 0.91 6.35 × 10−8
WDR61 Transcriptional regulation cg12339790 0.90 4.35 × 10−8
PGAP2 Protein transport cg01156876 0.90 1.24 × 10−8
DDX10 RNA helicase cg18585558 0.90 6.14 × 10−9
DGKH Kinase activity cg22899750 0.90 1.09 × 10−7
RAB40C Oncogene cg01770948 0.89 2.00 × 10−8
BEAN1 Not known cg19471156 0.89 5.59 × 10−8
HNSCC Tissue vs. Oral Lesions
EIF6 Eukaryotic Translation Initiation Factor 6 cg09957666 0.91 5.68 × 10−10
KANSL1 KAT8 Regulatory NSL Complex Subunit 1 cg07281649 0.91 1.43 × 10−9
DDX10 DEAD–Box Helicase 10 cg18585558 0.89 3.58 × 10−10
AP2A1 Adaptor Related Protein Complex 2 Alpha 1 Subunit cg08969148 0.89 8.97 × 10−10
RAB40C RAB40C, Member RAS Oncogene Family cg01770948 0.89 1.84 × 10−9
GAB1 GRB2 Associated Binding Protein 1 cg23020414 0.88 5.30 × 10−9
ERGIC1 Endoplasmic Reticulum-Golgi Intermediate Compartment 1 cg07769006 0.88 1.25 × 10−9
SNX14 Sorting Nexin 14 cg03776905 0.88 3.20 × 10−9
PIGU Phosphatidylinositol Glycan Anchor Biosynthesis Class U cg09450087 0.88 1.22 × 10−10
ARAP1 ArfGAP with RhoGAP Domain, Ankyrin Repeat, and PH Domain 1 cg09010791 0.87 1.56 × 10−9
LMTK2 Lemur Tyrosine Kinase 2 cg05941925 0.87 2.59 × 10−9
BEAN1 Brain Expressed Associated with NEDD4 1 cg19471156 0.87 6.96 × 10−9
AP1S3 Adaptor Related Protein Complex 1 Sigma 3 Subunit cg25666945 0.87 1.66 × 10−9
CDH1 Cadherin 1 cg08285862 0.87 2.28 × 10−8
RYBP RING1 and YY1 Binding Protein cg08086385 0.86 3.11 × 10−10
Int. J. Mol. Sci. 2020, 21, 6853 9 of 23
Table 3. Cont.
Gene Name Function cg Position MMD * p-Value **
Oral Lesions vs. Healthy Tissue
GRIP1 Glutamate Receptor Interacting Protein 1 cg09414535 0.68 0.000679
MTMR10 Myotubularin Related Protein 10 cg25430175 0.66 0.000585
RBM47 RNA Binding Motif Protein 47 cg11268702 0.66 0.000636
MPHOSPH9 M–Phase Phosphoprotein 9 cg02132191 0.65 0.001055
FOXK1 Forkhead Box K1 cg16026475 0.64 0.000765
SNX3 Sorting Nexin 3 cg14452952 0.64 0.000825
CIT Citron Rho-Interacting Serine/Threonine Kinase cg03601895 0.63 0.000866
ZBTB38 Zinc Finger and BTB Domain Containing 38 cg13318410 0.63 0.001548
DRD3 Dopamine Receptor D3 cg22253817 0.63 0.001115
SPPL3 Signal Peptide Peptidase Like 3 cg11330512 0.63 0.001072
ZNF407 Zinc Finger Protein 407 cg23863184 0.63 0.000942
ADAMTSL1 ADAMTS Like 1 cg12699984 0.62 0.000767
GNAT3 G Protein Subunit Alpha Transducin 3 cg10168361 0.62 0.000936
L3MBTL3 L3MBTL3, Histone Methyl-Lysine Binding Protein cg22162357 0.62 0.001083
EEPD1 Endonuclease/Exonuclease/Phosphatase Family Domain Containing 1 cg06387870 0.61 0.001083
* Mean difference (MD) across all sites in a region (mean.mean.diff); ** false discovery rate (FDR) adjustment combined p-value (comb.p.adj.fdr).
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Table 4. Hypomethylated CpG sites methylation in HNSCC tissue compared to control healthy tissue and potentially premalignant oral lesions, and in potentially
premalignant oral lesions compared to control healthy tissue. The list is merged of top fifteen differentially methylated genes according to the extent of methylation
difference value.
Gene Name Function cg Position MMD * p-Value **
HNSCC Tissue vs. Healthy Tissue
ATXN1 Not known cg07713291 −0.96 2.97 × 10−9
PPP2R2C Cell growth cg05805165 −0.93 1.22 × 10−8
CCR6 Immune regulation cg05094429 −0.92 1.08 × 10−7
RAB37 Oncogene cg25267982 −0.92 1.29 × 10−8
DUSP27 Phosphatase activity cg23713934 −0.91 1.94 × 10−7
ZNF521 Transcription factor cg21830945 −0.91 7.58 × 10−8
SLC6A17 Transporter cg12072789 −0.90 7.38 × 10−8
SPIN1 Methylated histone binding cg13554018 −0.90 1.63 × 10−8
CXCR1 Receptor cg13519373 −0.90 1.22 × 10−8
SPTBN1 Cell shape cg06149826 −0.89 6.91 × 10−9
NBAS Golgi to ER transport cg27424261 −0.89 5.31 × 10−7
NRG3 Ligand cg10656958 −0.89 9.45 × 10−8
COL5A1 Forming collagen cg26087052 −0.89 3.96 × 10−8
CDX1 Transcriptional regulation cg12473781 −0.89 5.77 × 10−8
BATF3 Transcriptional regulation cg03219362 −0.89 2.10 × 10−8
HNSCC Tissue vs. Oral Lesions
FAM69A Family with Sequence Similarity 69 Member A cg22727960 −0.93 7.05 × 10−11
ATP6V0A1 ATPase H+ Transporting V0 Subunit A1 cg19022525 −0.92 9.01 × 10−11
LBP Lipopolysaccharide Binding Protein cg18979491 −0.92 3.02 × 10−10
WDR25 WD Repeat Domain 25 cg24211276 −0.91 6.22 × 10−11
SH3RF3 SH3 Domain Containing Ring Finger 3 cg27294813 −0.91 1.01 × 10−9
NINJ2 Ninjurin 2 cg05534515 −0.91 2.74 × 10−12
RAB37 RAB37, Member RAS Oncogene Family cg25267982 −0.90 1.17 × 10−9
CXCR1 C-X-C Motif Chemokine Receptor 1 cg13519373 −0.90 1.76 × 10−10
SPTBN Spectrin Beta, Non–Erythrocytic 1 cg06149826 −0.90 1.54 × 10−10
RHOH Ras Homolog Family Member H cg15729055 −0.90 1.90 × 10−9
GRIK5 Glutamate Ionotropic Receptor Kainate Type Subunit 5 cg03100024 −0.90 2.47 × 10−9
KLRD1 Killer Cell Lectin Like Receptor D1 cg05377120 −0.90 6.88 × 10−9
TENM2 Teneurin Transmembrane Protein 2 cg26758826 −0.89 3.56 × 10−11
FAM69A Family with Sequence Similarity 69 Member A cg05172999 −0.89 3.14 × 10−10
ITK IL2 Inducible T Cell Kinase cg12250498 −0.89 3.46 × 10−10
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Table 4. Cont.
Gene Name Function cg Position MMD * p-Value **
Oral Lesions vs. Healthy Tissue
PHACTR1 Phosphatase and Actin Regulator 1 cg02381687 −0.80 0.000673
MARCH8 Membrane Associated Ring-CH-Type Finger 8 cg26841425 −0.80 0.000585
PPP1R1B Protein Phosphatase 1 Regulatory Inhibitor Subunit 1B cg03104421 −0.79 0.000585
HDAC4 Histone Deacetylase 4 cg21190228 −0.79 0.00057
IL22RA2 Interleukin 22 Receptor Subunit Alpha 2 cg23507945 −0.79 0.001772
CAMKK2 Calcium/Calmodulin Dependent Protein Kinase Kinase 2 cg03391567 −0.78 0.000679
INPP5D Inositol Polyphosphate-5-Phosphatase D cg22666015 −0.78 0.000709
CSGALNACT1 Chondroitin Sulfate N–Acetylgalactosaminyltransferase 1 cg24423468 −0.77 0.001266
GTDC1 Glycosyltransferase Like Domain Containing 1 cg19251811 −0.77 0.000676
IGSF3 Immunoglobulin Superfamily Member 3 cg13004173 −0.77 0.000585
HELZ Helicase with Zinc Finger cg15015109 −0.76 0.000772
DEFA4 Defensin Alpha 4 cg06617936 −0.76 0.000678
AK5 Adenylate Kinase 5 cg21487631 −0.76 0.000681
LHFPL2 LHFPL Tetraspan Subfamily Member 2 cg20879720 −0.76 0.000981
STK10 Serine/Threonine Kinase 10 cg22406187 −0.76 0.000765
* Mean difference (MD) across all sites in a region (mean.mean.diff); ** false discovery rate (FDR) adjustment combined p-value (comb.p.adj.fdr).
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2.6. Validation Panel
Pyrosequencing was performed on a subset of samples tested by the Infinium MethylationEPIC
BeadChip array (Illumina) for four gene promoters, namely SPRR3, FBXO2 (hypermethylated in
HNSCC tissue vs. control healthy tissue; Table 1), TRDC and LAIR2 (hypomethylated in HNSCC
tissue vs. control healthy tissue; Table 2) tested on four cancer samples and four control samples, each.
The selection criteria were the role of these genes in biological processes as well as the findings in
previous studies. SPRR3 (Small Proline Rich Protein 3) and FBXO2 (F-Box Protein 2) being largely
investigated; SPRR3 is involved in cornification, epidermis development, squamous cell differentiation,
and peptide cross linking [23], while FBXO2 is involved in the negative regulation of cell proliferation,
cellular protein modification, and protein ubiquitination [24]. In addition, the hypomethylated genes
in cancer are mostly involved in the immune response; TRDC (T Cell Receptor Delta Constant)
being involved in recognizing foreign antigens, which have been processed as small peptides and
bound to major histocompatibility complex (MHC) molecules at the surface of antigen presenting
cells [25]. LAIR-2 (Leukocyte Associated Immunoglobulin Like Receptor 2) related pathways belong
to the innate immune system, and class I MHC mediated antigen processing, and presentation and
immunoregulatory interactions [25].
For pyrosequencing validation, six amplifying PCR reactions (SPRR3-1, SPRR3-2, TRDC-1,
TRDC-2, LAIR2-1, LAIR2-2, FBXO2-1) with six sequencing primers have been performed to cover
four CpG sites for SPRR3, four CpGs for FBXO2, two CpGs for TRDC, and five CpGs for LAIR2
gene. The overall pyrosequencing data for tested CpGs were in agreement with the methylation array
data (Figure S2). However, statistical significance was only reached between HNSCC and the control
samples in CpG1 and CpG3 of SPRR3 gene (p = 0.01 in both cases) and CpG1 of FBXO2 gene (p = 0.01).
2.7. Gene Set Enrichment Data
Differentially methylated gene promotor regions were analyzed using the WebGestalt functional
enrichment analysis web tool to determine whether the affected genes are enriched for specific sets
of functions or pathways. Methylation data were explored with two different analysis approaches
available, over-representation enrichment analysis (ORA) and gene set enrichment analysis (GSEA).
The ORA of gene ontology (GO) data (biological processes) for consistently hypomethylated gene
promoters and/or CpG sites in one group of samples vs. the other group are presented in Figure 4.
The ORA of GO data (biological processes) for consistently hypermethylated gene promoters and/or
CpG sites in one group of samples vs. the other group are presented in Supplementary Materials
file (Figure S8). The top 10 GO categories are presented. The ORA analysis of KEGG pathway for
hypomethylated and hypermethylated gene promoters and/or CpG sites in one group of samples vs.
the other group are presented in Supplementary Materials file (Figures S7 and S9, respectively). The top
10 KEGG categories are presented. The GSEA analysis of GO biological processes for hypomethylated
and hypermethylated gene promoters and/or CpG sites in one group of samples vs. the other group
are presented in Supplementary Materials file (Figures S10 and S12, respectively). The GSEA analysis
of KEGG pathway for hypomethylated and hypermethylated gene promoters and/or CpG sites in one
group of samples vs. the other group are presented in Supplementary Materials file (Figures S11 and
S13, respectively).
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Figure 4. Over-representation enrichment analysis (ORA) of gene ontology (GO), biological processes, 
for consistently hypomethylated gene promoters and/or CpG sites in (A) HNSCC tissue compared to 
control healthy tissue, (B) HNSCC tissue compared to potentially premalignant oral lesions, and (C) 
potentially premalignant oral lesions compared to control healthy tissue. The top 10 categories are 
shown; the fold discovery rate (FDR) adjusted significance (colored bar) is in each shown case ≤ 0.05. 
2.8. External Database Validation 
Our gene promoters’ methylation findings were compared to TCGA Illumina HISeq RNAseq 
data of TCGA-HNSC project. The RNAseq estimation of expression for the top fifteen 
hypermethylated and top fifteen hypomethylated gene promoters in our results were visualized in 
Wanderer, an interactive viewer. The TCGA dataset included 497 tumor and 43 normal tissue 
samples. There was a good agreement between our gene promoters’ methylation data and the gene 
expression data (Table S1, Figures S3–S6). Out of the total of top fifteen hypermethylated gene 
promoters in our study, ten were found to be either under-expressed or hypermethylated in TCGA 
cancer cases, as expected, while one had no measurable expression and only a single CpG site in 
Illumina 450K DNA methylation array. From the top fifteen hypomethylated gene promoters in our 
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Figure 4. Over-representation enrichment analysis (ORA) of gene ontology (GO), biological processes,
for consistently hypomethylated gene promoters and/or CpG sites in (A) HNSCC tissue compared
to control healthy tissue, (B) HNSCC tissue compared to potentially premalignant oral lesions,
and (C) potentially premalignant oral le ions compared to control healthy tissue. The top 10 categories
are shown; the fold iscovery rate ( justed sign ficance (colored bar) is in each shown case ≤0.05.
2.8. External Database Valid t on
Our gene promoters’ methylation findings were compared to TCGA Illumina ISeq seq data
of TCGA-HNSC project. The RNAseq estimation of expression for the top fifteen hypermethylated and
top fifteen hypomethylated gene promoters in our results were visualized in Wanderer, n interactive
viewer. Th TCGA dat set included 497 tumor nd 43 normal tiss e samples. There wa a good
agreement between our gene promoters’ methylation data and the gene expression data (Table S1,
Figures S3–S6). Out of the total of top fifteen hypermethylated gene promoters in our study, ten were
found to b eith r under-expressed or hypermethylated in TCGA cancer cases, as expected, while one
had no measurable expression and only a single CpG site in Illu ina 450K DNA methylati n array.
From the top fifteen hypomethylated gene promoters in our study, twelve were also found to be either
over-expressed or hypomethylated in TCGA data, with the remaining three lacking annotated data or
probes in Illumina 450K DNA methylation array.
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3. Discussion
The aim of this study was to investigate DNA methylome in HNSCC and potentially premalignant
oral lesions, as well as in healthy oral tissue, and to identify the best genes that are differentially
methylated in gene promoters or specific sites among those groups of samples. We found that
components of different cellular pathways are differently methylated in HNSCC in comparison to
healthy oral tissue as well as potentially premalignant oral lesions.
Surprisingly, we could not observe any grouping of samples in accordance with their HPV status,
thus subsequent analysis focused only on the sample origin. The lack of HPV specific differences could
possibly be explained by a limited number of HPV positive samples (nine of 32). Furthermore, HPV is
known to be more associated with oropharyngeal tumors than oral cavity cancerogenesis [26]. Another
possible explanation is the particularity of the Croatian population where smoking and drinking are
almost equally present in HPV positive and HPV negative OPSCC patients shown in our previous
study [27]. On the other hand, the study of Lechner et al. with Infinium HumanMethylation450
BeadChips (Illumina) showed unsupervised clustering over the methylation variable positions of
samples in accordance with the HPV status. Nevertheless, they showed that HPV positive tumors are
heterogeneous, which led to the identification of a candidate CpG island methylator phenotype in a
sub-group of HPV positive tumors [28].
Herein, the top fifteen genes with a significant promoter hypermethylation in cancer tissues in
comparison to control healthy tissues, named GPRC5D, TMPRSS11B, PIAS2, ARG1, SRPK2, AADACL2,
RGPD4, SPRR3, DEGS1, TXNDC8, SH3TC1, ZPLD1, FBXO2, ATG16L1, and GRHL1 are mostly involved
in different cellular enzymatic reactions and in autophagy (Table 1). For example, the expression of
SPRR3 (Small Proline Rich Protein 3) was found to be associated with tumor cell proliferation and
invasion in glioblastoma multiforme. Liu et al. (2013) found, contrary to our findings, that SPRR3
hypomethylation was associated with the clinical outcome in glioblastoma multiforme patients [29].
In an anatomically more similar context, SPRR3 was frequently downregulated in OPSCC where it
probably suppresses tumorigenicity [30]. In our study, we selected the promoter of the SPRR3 and
FBXO2 genes for validation by pyrosequencing and found that both methods agree on the direction of
methylation deregulation, which is hypermethylation of the gene promotor.
The top fifteen genes in cancer tissues that were found in this study to be significantly
hypomethylated in their promoters in comparison to control healthy tissues (TRBC2, DGAT2, ALG1L,
PDE4D, TRDC, DNAJC6, IGKV3-20, TMEM150B, LAIR2, UBQLN3, ANKFN1, MS4A1, CCT8L2, SPOCK1,
and IGHV4-39) are mainly involved in the immune response, i.e., IGHV4-39 (antigen recognition gene),
IGKV3-20 (immunoglobulin receptor binding gene), LAIR2 (innate immune response gene), MS4A1
(differentiation of B cells gene), TRBC2 and TRDC (both T cell receptor genes). Indeed, the HNSCC are
known for their immune-suppressive character allowing tumor evasion and escape from the immune
surveillance, which probably can be associated with the methylation of immune-response related
genes [31]. Here again, from the list of genes with hypomethylated promoters we selected LAIR2 and
TRDC for validation and, as expected, both gave comparable results on pyrosequencing.
The top fifteen significantly hypermethylated genes, named LMBR1L, CDH1, EIF6, C16orf70,
ETNK2, C11orf73, ADARB2, GAB1, ITPR3, WDR61, PGAP2, DDX10, DGKH, RAB40C, and BEAN1 on
different gene sites (mostly in 5′UTR and body) in cancer tissues in comparison to control healthy oral
tissues are mostly involved in translational processes and cellular growth, along with transformation
and proliferation. Among them, CDH1, ETNK2, ADARB2, and RAB40C are found to be aberrantly
methylated in different cancers [32–35]. For instance, altered methylation levels of CDH1 (Cadherin 1),
whose loss contributes to cancer progression by increasing proliferation, invasion, and/or metastasis
are recorded in oral cavity [32], oral [36], and in cervical cancer [37]. The study of Strzelczyk et al. [32]
reported a significantly higher methylation level of CDH1 in tumor tissues compared to surgical
margins (57% vs. 25% p < 0.001) in patients with oral cavity cancer. The meta-analysis of the gene
promoter hypermethylation in oral cancer, that included 29 studies of which 13 were about CDH1
methylation, showed a significant correlation of CDH1 hypermethylation with oral cancer risk [36].
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Moreover, in the meta-analysis of Liu et al. [37] on patients with cervical carcinoma, CDH1 promoter
methylation was significantly higher in cancer than in cervical intraepithelial neoplasia lesions and
healthy cervical tissues.
The first fifteen genes that were significantly hypomethylated on different sites across the genome
in cancer tissues in comparison to control healthy tissues, named ATXN1, PPP2R2C, CCR6, RAB37,
DUSP27, ZNF521, SLC6A17, SPIN1, CXCR1, SPTBN1, NBAS, NRG3, COL5A1, CDX1, and BATF3 are
mostly involved in transcriptional and immune regulation. Among this group of genes, aberrantly
methylated in other human cancers were CCR6 in oral cancer [38] and chronic lymphocytic leukemia [39],
RAB37 in lung cancer [40], ZNF521 in breast cancer [41], and CDX1 in gastric cancer [42], esophageal
SCC [43], and in colon cancer [44]. The genes involved in the immune regulation could belong to
the tumor-infiltrating immune cells or tumor-infiltrating lymphocytes, which are often associated
with better clinical outcomes. Thus, the aberrantly methylated gene CCR6 (C-C Motif Chemokine
Receptor 6), which regulates the migration and recruitment of dendritic and T cells during inflammatory
and immunological responses, was also found in human OSCC [38]. Lee et al. [38] concluded that
hypomethylation of this gene may play an important role in the recruitment or retention of CCR6+
Treg cells into the OSCC inflammatory microenvironment at the early stage of tumor progression.
In addition, a genome-wide DNA methylation analysis of chronic lymphocytic leukemia patients
in comparison to healthy donors identified the differently methylated CCR6 gene, among other
immune regulatory genes [39]. In addition, in their study, Kim et al. presented that the majority of
hypomethylated gene sets identified across multiple cancer (breast, lung cancer, colorectal, myeloma,
glioblastoma, ovarian, kidney and stomach cancer) studies were immune-related, suggesting DNA
methylation-driven cancer cell invasion and tumorigenesis across various types of cancer [45].
The external validation of our top thirty differentially methylated gene promoters in HNSCC vs.
control tissue with gene expression data in human cancer through Wanderer, an interactive viewer,
gave a very good agreement. In summary, the majority of hypermethylated gene promoters in HNSCC
in our study (10 of 15) were found to be either under-expressed or hypermethylated in TCGA cancer
cases. In addition, from the top 15 hypomethlylated gene promoters in our study, 12 were also found
to be either over-expressed or hypomethylated in TCGA data.
Of particular interest in the HNSCC diagnostic, clinical prognosis and/or risk assessment could
be the methylation of CDH1, which was also previously described as a possible biomarker for the
early detection and treatment of HNSCC [32,36,46,47]. We also validated the CDH1 gene promoter in
the same groups of cancer samples and healthy controls by Methylation-Specific PCR (MSP), and the
findings are in concordance with the Infinium MethylationEPIC BeadChip array findings (data not
presented). The majority of HNSCC samples (85%) were methylated in the CDH1 gene promoter by
MSP, while only 21% of healthy control samples were methylated in the same gene promoter. In this
study, we found the CDH1 gene to be significantly hypermethylated on specific sites in the genome
(body) on a high second place in cancer tissues in comparison to control tissues. The same gene (CDH1)
is also among the top fifteen genes that are significantly hypermethylated on different sites across the
genome in cancer tissues compared to lesions. The CDH1 gene encodes E-cadherin, a classical cadherin
of the cadherin superfamily that is involved in mechanisms regulating cell-cell adhesions, mobility,
and proliferation of epithelial cells. It is recognized as a tumor suppressor gene; the loss of function of
this gene is thought to contribute to cancer progression by increasing proliferation, invasion, and/or
metastasis [25]. Hence, we showed herein that hypermethylation on specific CpGs within the CDH1
gene could be a good biomarker of HNC and a possible option to distinguish HNSCC from potentially
premalignant oral lesions and from healthy oral mucosa as well.
Two other genes that are present in the top fifteen most significantly hypermethylated in gene
promoter regions in cancer tissues compared to lesions, and in lesions compared to control healthy
tissues are the SLC5A10 (Solute Carrier Family 5 Member 10) and the TBC1D2 (TBC1 Domain Family
Member 2) gene. The SLC5A10 gene is a member of the sodium/glucose transporter family, while the
TBC1D2 gene acts as GTPase-activating protein for RAB7A, involved in cadherin degradation and
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cell-cell adhesion. Notably, two out of the three genes, whose hypermethylation may be of particular
importance in HNSCC diagnostic, CDH1 and TBC1D2, are involved in cadherin regulation of cell-cell
adhesion. Suppression of cadherins in HNSCC leads to cells escaping from the contact-dependent
growth, which develop a migratory phenotype with low differentiation stage, suggesting that cadherins
contribute to the transformation steps [48]. The two genes from the group, SLC5A10 and TBC1D2,
could also be considered as possible good methylation biomarkers to distinguish oral potentially
premalignant lesions from healthy oral tissue.
Unexpectedly, the overlap of significant findings on the CpG site and gene promoter levels in the
whole study was non-existent, probably because most of the top-rated promoters included only one or
rarely few sites in the analysis. Further, there is no evidence in the literature on this issue to conform or
refute these observations.
Using the WebGestalt functional enrichment analysis web tool we assessed gene enrichment for
specific sets of functions or pathways and networking. Indeed, the over-representation enrichment
analysis (ORA) of GO non-redundant biological processes for differentially methylated gene promoters
presented an implication of mostly immune response and cellular defense response pathways, as well
as cell-cell adhesion.
The current study is the first to implement the Infinium MethylationEPIC BeadChip assay on a
well-defined set of clinical samples encompassing the whole possible spectrum from healthy tissue to
cancer. To our knowledge, this is the first such study focused on HNSCC, oral lesions, and healthy
tissue together. In addition, the power of the study relies on prospectively collected fresh samples
with minimum delays between sample collection and processing. However, for that reason the
limitation of the study might be the possibility that infiltrating immune cells could be present in
tumor tissues. Indeed, we performed the analysis of tumor purity by leukocytes unmethylation
for the purity (LUMP) method [49] and assessed the variability of the tissue cellular composition
(Figure S14): Different amounts of infiltrating immune cells for every group of samples, with a
significantly lower proportion (p < 0.05) of the same in a healthy oral tissue (20%) than in HNSCC
(56%) and lesions’ samples (65%). In addition, one of the strengths of this study was the simultaneous
microarray testing in the same analysis of different tissues, cancer, oral lesions, and healthy tissue.
On the other hand, the study was limited by anatomical differences in the sample material, namely
both healthy and potentially premalignant oral lesions samples were mostly derived from the oral
cavity, where potentially premalignant oral lesions usually originate, while cancer samples included
both oral, and oropharyngeal cancer. Another possible limitation was the age of participants as
cancer usually develops later in life, while the average age of controls and patients with potentially
premalignant oral lesions was lower (43 vs. 53 years). We attempted to adjust for this by including age
as a covariate. For the future study, we plan to collect also the healthy oral mucosa from the same
patient to investigate possible differences. Overall, our study has demonstrated a significant overlap
with current knowledge, which together with successful validation of the data by pyrosequencing
confirms the reliability of the underlying data and strengthens its results.
4. Materials and Methods
4.1. Study Group
Healthy oral mucosa samples were collected from healthy subjects in the School of Dental
Medicine, University of Zagreb, Croatia, during a regular process of teeth extraction from 2010 to
2017. Oral samples of potentially premalignant oral lesions, OLP and OLL, were taken cytologically in
the School of Dental Medicine, University of Zagreb, Croatia, from 2008 to 2016. HNSCC samples
were collected in the Clinical Hospital Dubrava, Zagreb, Croatia, from 2014 to 2018. The study
group comprised 32 oral samples: nine healthy oral mucosa, 10 potentially premalignant oral lesions
(eight OLP and two OLL), and 13 HNSCC (six oropharyngeal cancers and seven oral cancers).
The tmedian age among patients with HNSCC was 57 years, while amongst patients with potentially
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premalignant oral lesions and control healthy mucosa was slightly lower, 43 and 53 years, respectively.
There were 10 men and three women with HNSCC, four men and six women with potentially
premalignant oral lesions, and four men and five women with healthy oral mucosa and without
drinking and smoking history. Fresh samples were collected with the cytobrush, stored in appropriate
buffers for further analysis, HPV testing, and DNA methylation analysis.
4.2. DNA Preparation
The extracted DNA from oral specimens was processed without initial knowledge of patients’
data. DNA was isolated using the BioRobot EZ1 (Qiagen, Hilden, Germany) system according to the
manufacturer’s instructions. After DNA extraction, the purified DNA was dissolved in 50–100 µL of
tri-distillate sterile water and stored at −20 ◦C until further analysis. The quality and integrity of the
samples were evaluated on a NanoPhotometer (Implen GmbH, München, Germany), and samples
with the ratio A260/280 between 1.7–1.9 were included in the study [50].
4.3. HPV Detection and Typing
HPV testing is previously described [51,52]. Briefly, three sets of consensus primers for HPV
detection were used: PGMY09/PGMY11, L1C1/L1C2-1/L1C2-2, and GP5+/GP6+. The quality of the
isolated DNA was confirmed by amplification of the β-globin gene using PC04/GH20 primers in
a multiplex polymerase chain reaction (PCR) with PGMY primers. Type-specific (TS) primers
for HPV types 6/11, 16, 18, 31, 33, 45, 52, and 58 were used for HPV typing according to
Milutin-Gasperov et al. [51]. Aliquots of each PCR product (10 µL) were analyzed by a 2% agarose gel
electrophoresis and stained with Midori Green Advance dye. The amplified products were visualized
by UV irradiation of the gels using the UVItec Cambridge (Alliance 4.7) imaging system. HPV positive
samples that were not positive for TS-PCR but positive for consensus primer amplification were defined
as undetermined HPV type.
4.4. Methylation Array Analysis
The Infinium MethylationEPIC BeadChip array (Illumina), which integrates a total of 863,904 CpG
loci, together with 2932 non-CpG loci and 59 single nucleotide polymorphisms (SNPs), superseded
the HM450 array, while still containing more than 90% of the original HM450 probes. Additional
probes included in the new version of the array greatly increased the power of this microarray to study
enhancer/regulatory regions [53]. Briefly, approximately 1–2 µg of DNA from cancer and oral samples
were modified with sodium bisulfite using the EZ DNA Methylation Kit (Zymo Research, Irvine,
CA USA) and then purified according to the manufacturer’s instructions. After bisulfite treatment,
180–200 ng DNA was subjected to the whole genome amplification (WGA) and enzymatic digestion
with the Infinium MethylationEPIC BeadChip kit reagents. The hybridization of the samples on the
BeadChips and washing procedures followed the standard manufacturer’s protocol. The iScan System
(Illumina) was used to read the BeadChips.
4.5. Data Processing and Statistical Analysis
Raw data obtained by iScan readout was imported to and analyzed within R using ChAMP
(version 2.9.10) [54] and RnBeads packages (version 1.10.7; integrated software package for the
analysis and interpretation of DNA methylation data) [55]. Briefly, data were imported to the Chip
Analysis Methylation Pipeline (ChAMP) pre-processed, and normalized with the Peak Based Correction
(PBC) method [56]. Subsequently, the Combat method [57] within ChAMP was used to adjust for
batch effects. The resulting normalized and batch-corrected rnb.set was imported to the RnBeads
package for subsequent exploratory and differential methylation analysis and customized visualization.
RnBeads uses the limma normalization method (linear models for microarray data) [58] for differential
methylation assessment between pairs of groups and herein the calculations were performed while
adjusting for patient age and gender as covariates. In addition to analyzing differential methylation
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between groups on the individual CpG site level, all analyses were performed on the predefined gene
and promoter levels by selecting appropriate region.types options within the RnBeads package.
4.6. Differentially Methylated Gene Promoters and Individual CPG Sites
The resulting differentially methylated promoter or CpG site lists were further filtered by selecting
only promoters or sites with false discovery rate (FDR) adjusted p-values ≤ 0.05 and mean methylation
difference ≥ |0.2|. For the top 15 candidates presented in Tables 1–4, a more stringent differential
methylation value of ≥ |0.44| is presented (between cancer and control healthy tissues, cancer and
potentially premalignant oral lesions, and potentially premalignant oral lesions and control healthy
tissues). The filtered tables contain the information on chromosome locations, and relation to any
nearby CpG islands. Promoter level data additionally contains information about the number of
included CpG sites and average GC content for the region.
4.7. Validation of Methylation by Pyrosequencing
Pyrosequencing assays were developed for the following genes: SPRR3, FBXO2, TRDC, and LAIR2.
The PCR and sequencing primers were designed using the PyroMark Assay Design software, version
2.0.1.15 (Qiagen) to assess individual CpG sites of depicted genes from the Infinium MethylationEPIC
BeadChip array analysis. All primers were purchased from Macrogen (Macrogen, Seoul, South Korea).
The primer sequences, amplicon sizes, and the optimal annealing temperatures are indicated in Table S1.
The analysis was performed on four control healthy and four HNSCC tissues (two HPV positive and
two HPV negative), which were already tested by the Infinium MethylationEPIC BeadChip array.
Briefly, approximately 500 ng of extracted DNA was used for the bisulfite treatment performed with
the EZ DNA Methylation Kit, according to the instructions by the manufacturer, and eluted in a 20 µL
elution buffer (Zymo Research). The PCR reactions were performed according to the PyroMark PCR
protocol (Qiagen) in a total volume of 30 µL. Briefly, 0.10 µmol/L of each primer, 1.5 mM MgCl2,
PyroMark PCR Master mix (Qiagen), Coral Load (Qiagen), and 50 ng of bisulfite treated template
DNA were added to the PCR reaction and performed in a thermocycler (Veriti, 96 Well Thermal Cycler,
Applied Biosystems, Foster City, California, USA). The program was as follows: Initial denaturation of
1 min at 95 ◦C, followed by 45 cycles of 30 s denaturation at 95 ◦C, specific annealing temperature for
each primer pair (Table S1) for 30 s, and extension for 30 s at 72 ◦C with the final extension for 10 min at
72 ◦C. Pyrosequencing was performed using a PyroMark Q24 Reagent Kit and a PyroMark Q24 system
(Qiagen) as described previously by Mikeska et al. [59]. The nucleotide addition order was optimized
by the PyroMark Q24 Software (Qiagen) and the results were automatically analyzed using the same
software. The percentage of methylation for each CpG island between the two sample groups (cancer
vs. controls) was compared and p-values were determined using the t-test.
4.8. Gene Set Enrichment Analysis
The list of differentially methylated gene promotor regions was assessed to determine whether
the affected genes are enriched for specific sets of functions or pathways. However, for the analysis,
only those regions with assigned RefGene names indicating nearby or overlapping genes were selected.
To make the analysis more stringent, only promotors with at least two CpG sites were included.
The analysis was done using the WebGestalt functional enrichment analysis web tool [60]. Methylation
data were explored with two different analysis approaches available, over-representation enrichment
analysis (ORA) and gene set enrichment analysis (GSEA). For the ORA and GSEA analysis, the gene
ontology—biological process (no-redundant) and KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathway databases were chosen. For ORA, the reference gene set was set to the whole genome,
since many differentially methylated regions were related to miRNA and other non-coding sequences.
For GSEA, gene promotors were ranked according to the Log2 of the mean difference and this data
were supplied in addition to the gene symbol.
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4.9. External Validation of Differentially Methylated Gene Promoters
Our gene promoters’ methylation findings were compared to Illumina HISeq RNAseq data of the
TCGA-HNSC project through Wanderer (http://maplab.imppc.org/wanderer/), an interactive viewer to
explore DNA methylation and gene expression data in human cancer [61]. The RNAseq estimation
of expression for the top fifteen hypermethylated and top fifteen hypomethylated gene promoters
in our results were visualized in Wanderer. The TCGA dataset included 497 tumor and 43 normal
tissue samples. In the cases where the direction of expression change did not correspond with our
methylation change, we visualized complementary TCGA in Illumina 450K DNA methylation array
results for the same genes.
4.10. Ethics Approval and Consent to Participate
This study was approved by the Ethical Board of the Rud̄er Bošković Institute (18 June 2014),
the Ethical Board of the Clinical Hospital Dubrava (10 June 2014), and the School of Dental Medicine
(10 June 2014), University of Zagreb. The study is in line with the Helsinki Declaration (adopted
by the 18th WMA General Assembly, Helsinki, Finland, June 1964; amended by the 29th WMA
General Assembly, Tokyo, Japan, October 1975; 35th WMA General Assembly, Venice, Italy, October
1983; 41st WMA General Assembly, Hong Kong, September 1989; 48th WMA General Assembly,
Somerset West, Republic of South Africa, October 1996, and the 52nd WMA General Assembly,
Edinburgh, Scotland, October 2000) An informed consent to participate in the study was obtained from
each participant.
5. Conclusions
The presented methylation clustering shows that the potentially premalignant oral lesions (OLL and
OLP) are more closely related to healthy mucosa than to the HNSCC although differences between
groups exist. The identified panels of hypermethylated and hypomethylated genes, which differentiate
the HNSCC samples from oral potentially premalignant lesions and healthy mucosa could clinically
be a useful tool for early cancer diagnosis and prognosis. Specific genes that could be considered as
HNSCC DNA methylation biomarkers belong to the group of receptor genes, transcription factors,
genes involved in adhesion and transport reactions, as well as genes related to the immune response.
Thus, the HNSCC hypermethylated CDH1 gene, involved in cell-cell adhesion, could be considered as
a good biomarker for distinguishing cancer tissues from potentially premalignant oral lesions and from
healthy oral mucosa. In addition, hypermethylated gene promoters of SLC5A10, involved in transport,
and TBC1D2, involved in cell-cell adhesion, could be also good biomarkers for distinguishing HNSCC
from lesions, as well as potentially premalignant oral lesions from healthy oral tissues.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/18/
6853/s1.
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